Your browser doesn't support javascript.
loading
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
Fujii, Hideki; Suzuki, Yuichiro; Sawada, Koji; Tatsuta, Miwa; Maeshiro, Tatsuji; Tobita, Hiroshi; Tsutsumi, Tsubasa; Akahane, Takemi; Hasebe, Chitomi; Kawanaka, Miwa; Kessoku, Takaomi; Eguchi, Yuichiro; Syokita, Hayashi; Nakajima, Atsushi; Kamada, Tomoari; Yoshiji, Hitoshi; Kawaguchi, Takumi; Sakugawa, Hiroshi; Morishita, Asahiro; Masaki, Tsutomu; Ohmura, Takumi; Watanabe, Toshio; Kawada, Norifumi; Yoda, Yoshioki; Enomoto, Nobuyuki; Ono, Masafumi; Fuyama, Kanako; Okada, Kazufumi; Nishimoto, Naoki; Ito, Yoichi M; Kamada, Yoshihiro; Takahashi, Hirokazu; Sumida, Yoshio.
Afiliação
  • Fujii H; Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Suzuki Y; First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Sawada K; Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
  • Tatsuta M; Department of Gastroenterology, KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan.
  • Maeshiro T; First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
  • Tobita H; Department of Hepatology, Shimane University Hospital, Izumo, Shimane, Japan.
  • Tsutsumi T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Akahane T; Department of Gastroenterology, Nara Medical University, Kashihara, Nara, Japan.
  • Hasebe C; Department of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Hokkaido, Japan.
  • Kawanaka M; Department of General Internal Medicine 2, Kawasaki Medical Center, Kawasaki Medical School, Kita, Okayama, Japan.
  • Kessoku T; Kanagawa Dental University Yokohama Clinic, Yokohama, Japan.
  • Eguchi Y; Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital, Chiba, Japan.
  • Syokita H; Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Nakajima A; Loco Medical General Institute, Saga, Japan.
  • Kamada T; Department of Gastroenterology, Northern OKINAWA Medical Center, Nago, Okinawa, Japan.
  • Yoshiji H; Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kawaguchi T; Department of Health Care Medicine, Kawasaki Medical School, Kita, Okayama, Japan.
  • Sakugawa H; Department of Gastroenterology, Nara Medical University, Kashihara, Nara, Japan.
  • Morishita A; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Masaki T; Department of Gastroenterology, Heartlife Hospital, Okinawa, Japan.
  • Ohmura T; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Watanabe T; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Kawada N; Department of Health Care, Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan.
  • Yoda Y; Department of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Enomoto N; Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Ono M; JA Yamanashi Koseiren Health Care Center, Yamanashi, Japan.
  • Fuyama K; First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Okada K; Division of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Nishimoto N; Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.
  • Ito YM; Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.
  • Kamada Y; Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.
  • Takahashi H; Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.
  • Sumida Y; Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hepatol Res ; 53(11): 1059-1072, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37537735
ABSTRACT

AIM:

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. The aim of this study was to determine the recent prevalence and clinical characteristics of NAFLD in Japan.

METHODS:

This study initially included 410 061 retrospectively enrolled adults from the medical health checkup registry for metabolic syndrome, chronic kidney disease, and fatty liver in Japan (MIRACLE-J; UMIN-CTR no. UMIN000049419), who were evaluated between 2014 and 2018 at 13 health centers in Japan. Individuals consuming >20 g of alcohol/day or with chronic liver disease were excluded. Fatty liver was diagnosed by ultrasonography. The probability of NAFLD with advanced fibrosis was estimated based on the fibrosis-4 index and NAFLD fibrosis score.

RESULTS:

A total of 71 254 participants were included in the final analysis. The overall prevalence of NAFLD was 25.8%. There was a significant, twofold difference in NAFLD prevalence between men (37.4%) and women (18.1%). Nonalcoholic fatty liver disease prevalence increased linearly with body mass index, triglycerides, and low-density lipoprotein cholesterol regardless of threshold values, even in the absence of obesity. Among patients with NAFLD, 14% had diabetes mellitus, 31% had hypertension, and 48% had dyslipidemia. The estimated prevalence of NAFLD with advanced fibrosis was 1.7% and 1.0% according to the fibrosis-4 index and NAFLD fibrosis score, respectively.

CONCLUSIONS:

The prevalence of NAFLD was approximately one-quarter of the general population in Japan. There was a linear relationship between NAFLD prevalence and various metabolic parameters, even in nonobese participants. The prevalence of NAFLD with advanced fibrosis was estimated to be 1%-2%.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article